Cosmesis and Breast-Related Quality of Life Outcomes After Intraoperative Radiation Therapy for Early Breast Cancer: A Substudy of the TARGIT-A Trial
Overview
Authors
Affiliations
Purpose: To report the first comprehensive investigation of patient-reported cosmesis and breast-related quality of life (QOL) outcomes comparing patients randomized to risk-adapted single-dose intraoperative radiation therapy (TARGIT-IORT) versus external beam radiation therapy (EBRT) on the TARGIT-A trial.
Methods And Materials: Longitudinal cosmesis and QOL data were collected from a subset of TARGIT-A participants who received TARGIT-IORT as a separate procedure (postpathology). Patients completed a cosmetic assessment before radiation therapy and annually thereafter for at least 5 years. Patients also completed the combined European Organization for Research and Treatment of Cancer (EORTC) core questionnaire and Breast-Specific Module in addition to the Body Image after Breast Cancer Questionnaire at baseline and annually thereafter. The combined EORTC questionnaires were also collected 3, 6, and 9 months after wide local excision.
Results: An Excellent-Good cosmetic result was scored more often than a Fair-Poor result for both treatment groups across all time points. The TARGIT-IORT patients reported better breast-related QOL than EBRT patients. Statistically and clinically significant differences were seen at month 6 and year 1, with EBRT patients having moderately worse breast symptoms (a statistically significant difference of more than 10 in a 100-point scale) than TARGIT-IORT patients at these time points.
Conclusion: Patients treated with TARGIT-IORT on the TARGIT-A trial have similar self-reported cosmetic outcome but better breast-related QOL outcomes than patients treated with EBRT. This important evidence can facilitate the treatment decision-making process for patients who have early breast cancer suitable for breast-conserving surgery and inform their clinicians.
Burkon P, Selingerova I, Vrzal M, Holanek M, Coufal O, Polachova K Sci Rep. 2025; 15(1):1387.
PMID: 39779797 PMC: 11711455. DOI: 10.1038/s41598-025-85342-2.
Gao S, Lin T, Liu L, Chen W, Liang J Breast Cancer Res. 2024; 26(1):181.
PMID: 39695713 PMC: 11657178. DOI: 10.1186/s13058-024-01936-0.
Chi M, Ko H, Yang T, Liu Y, Chi K, Cheng F Front Oncol. 2024; 14:1411598.
PMID: 39439951 PMC: 11493767. DOI: 10.3389/fonc.2024.1411598.
Bhimani F, McEvoy M, Chen Y, Gupta A, Pastoriza J, Fruchter S Front Oncol. 2024; 14:1429326.
PMID: 39381035 PMC: 11458558. DOI: 10.3389/fonc.2024.1429326.
Gunster J, Jacobs D, Mast M, Verbeek-de Kanter A, Fisscher U, Petoukhova A Clin Transl Radiat Oncol. 2024; 49:100844.
PMID: 39308632 PMC: 11416622. DOI: 10.1016/j.ctro.2024.100844.